Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December....
By CNBC ยท CNBC
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.